ライフサイエンスコーパス: hemagglutination

1 tagenesis to identify two genes required for hemagglutination.

2 Serum anti-A antibodies were assessed by hemagglutination.

3 Loss of hemagglutination ability results in attenuation.

4 rticles (VLPs) carrying these mutations lost hemagglutination ability, showed different ganglioside s

5 ind to IAV and inhibit viral infectivity and hemagglutination activity in vitro.

6 HNPs 1 and 2 did not inhibit viral hemagglutination activity, but they interfered with the

7 le all mutants reacquired various degrees of hemagglutination activity.

8 bohydrates and glycoproteins inhibited their hemagglutination activity.

9 ayer has been isolated, and shown to mediate hemagglutination, adhesion/invasion of epithelial cell,

10 briae are characterized by mannose-sensitive hemagglutination and are assembled via the chaperone/ush

11 H binding affinity based on their effects on hemagglutination and biofilm formation along with direct

12 The striking correlation between the ranked hemagglutination and endogenous sialidase activities of

13 The binding was demonstrated by hemagglutination and saliva binding assay using recombin

14 reviously described HA nanoparticles mediate hemagglutination and then determined that the Y98F mutat

15 A) is sensitive and a CSF Treponema pallidum hemagglutination assay (CSF-TPHA) titer of >/=1:640 is s

16 An indirect hemagglutination assay (IHA) is used as a reference sero

17 Virus dilution (hemagglutination assay titer, 512) of 0.156 vol% was rea

18 Initially demonstrated by hemagglutination assay with human erythrocytes and intac

19 In contrast to the hemagglutination assay, the ABO-glycan microarray allows

20 rior exposure to B. pseudomallei by indirect hemagglutination assay.

21 3-5 d via reverse-transcription (RT)-PCR or hemagglutination assay.

22 tional characterization of the protein using hemagglutination assays revealed lectin activity.

23 interpreting anti-ABO antibodies measured by hemagglutination assays with reagent erythrocytes.

24 Hemagglutination assays, receptor-destroying enzyme acti

25 using molecular assays, virus isolation, and hemagglutination assays.

26 city of glycan binding was confirmed through hemagglutination assays; GST-VP8* P[11] hemagglutinates

27 ell, and monocyte responses) correlated with hemagglutination at day 28.

28 A hemagglutination-based assay with E. coli expressing mut

29 could block carbohydrate binding and inhibit hemagglutination by NV rVLP.

30 2005 to 2009 has been the poor inhibition of hemagglutination by postinfection ferret antisera for ma

31 damage and increased in vitro inhibition of hemagglutination by SP-D.

32 The T3-specific antibody inhibited hemagglutination by T3 virions but not ISVPs, indicating

33 ad range of H7 subtype viruses and inhibited hemagglutination by the novel H7 hemagglutinin.

34 The T1-specific antibody inhibited hemagglutination by virions and ISVPs, probably via dire

35 The mutant library was screened for hemagglutination deficiency, and three clones were isola

36 d as G in virus designations) and either the hemagglutination (HA [H]) or the nucleoprotein (NP [P])

37 s by electron microscopy; however, its viral hemagglutination (HA) activity was not inhibited by anti

38 say and submicromolar cellular activity in a hemagglutination (HA) functional cell assay of bacterial

39 f measuring ABO antibody levels based on the hemagglutination (HA) titers have the disadvantages of r

40 (HN) is a multifunctional protein mediating hemagglutination (HA), neuraminidase (NA), and fusion pr

41 Indirect hemagglutination (IHA) is typically used to serotype thi

42 esidues that are required for CFA/I-mediated hemagglutination, implicating this as the receptor-bindi

43 -2,3-didehydro-N-acetylneuraminate inhibited hemagglutination in a pattern correlated with endogenous

44 ional activities as potency in inhibition of hemagglutination induced by class 5 fimbria-bearing ETEC

45 Subjects had minimal pre-existing hemagglutination inhibiting (HAI) antibodies and TIV ind

46 examined the association of pre-existing NA, hemagglutination inhibiting, and HA stalk antibody level

47 viruses that we tested raised high levels of hemagglutination-inhibiting (1:160-1:1280) and virus-neu

48 -49 years and 50-70 years) with undetectable hemagglutination-inhibiting (HAI) antibody to H7N9 were

49 though vaccinated birds had higher titers of hemagglutination-inhibiting (HI) antibodies against the

50 Hemagglutination-inhibiting (HI) antibodies and cellular

51 broadly neutralizing antibodies that have no hemagglutination-inhibiting activity and are less potent

52 ation activity, but they interfered with the hemagglutination-inhibiting activity of SP-D.

53 ts but not control subjects generated strong hemagglutination-inhibiting and neutralizing antibody re

54 y distant H1N1 strains than the conventional hemagglutination-inhibiting and neutralizing MAbs.

55 otein preparations from both lineages raised hemagglutination-inhibiting antibodies against H7N9 viru

56 none of these sera had detectable levels of hemagglutination-inhibiting antibodies against the H7N9

57 virus (HIV) infection and the persistence of hemagglutination-inhibiting antibodies in mothers and in

58 , a RIG-I ligand, developed robust levels of hemagglutination-inhibiting antibodies, enhanced germina

59 Comparison of hemagglutination-inhibiting geometric mean titers to inf

60 ted antibodies with differential patterns of hemagglutination inhibition (HAI) activity against a pan

61 oteins (X1, X3, X6, and P1) had the broadest hemagglutination inhibition (HAI) activity against a pan

62 g COBRA HA proteins elicited antibodies with hemagglutination inhibition (HAI) activity against more

63 Hemagglutination inhibition (HAI) and microneutralizatio

64 Rates of hemagglutination inhibition (HAI) and neuraminidase inhi

65 l and across all three clades as measured by hemagglutination inhibition (HAI) and neutralization ass

66 Serum hemagglutination inhibition (HAI) and neutralizing (Neut

67 sted for H1/stalk immunoglobulin G (IgG) and hemagglutination inhibition (HAI) antibodies prevaccinat

68 a secondary analysis of a subset of infants, hemagglutination inhibition (HAI) antibodies were measur

69 ine trials, we assessed their cross-reactive hemagglutination inhibition (HAI) antibody responses aga

70 Hemagglutination inhibition (HAI) antibody responses to

71 erase chain reaction (RT-PCR), and the serum hemagglutination inhibition (HAI) antibody titer, were a

72 BRA T10 HA antigen elicited sera with higher hemagglutination inhibition (HAI) antibody titers than a

73 Adverse reactions were assessed, and hemagglutination inhibition (HAI) antibody titers were d

74 Antibodies were measured by hemagglutination inhibition (HAI) assay at baseline, 21-

75 The hemagglutination inhibition (HAI) assay is the primary m

76 Immune responses were measured with a hemagglutination inhibition (HAI) assay, and influenza w

77 ated influenza vaccine (LAIV) were tested by hemagglutination inhibition (HAI) assay, microneutraliza

78 Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays.

79 Antibody titers measured by hemagglutination inhibition (HAI) correlate with protect

80 There was no hemagglutination inhibition (HAI) cross-reactivity in fe

81 Hemagglutination inhibition (HAI) geometric mean titers

82 We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhib

83 ost effective regimens elicited the broadest hemagglutination inhibition (HAI) response against a pan

84 nin could not be detected after infection by hemagglutination inhibition (HAI) test with avian and se

85 showed an improved response, with a positive hemagglutination inhibition (HAI) titer in 91% of recipi

86 A serum hemagglutination inhibition (HAI) titer of 40 or greater

87 C-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in S

88 ntibody responses, especially IgA levels and hemagglutination inhibition (HAI) titers, more than 8-mo

89 fluenza-specific antibodies were measured by hemagglutination inhibition (HAI), and T cells were stud

90 lack of antibody cross-reactivity to ICV in hemagglutination inhibition (HI) and agar gel immunodiff

91 Hemagglutination inhibition (HI) and gene sequencing exp

92 by sera diluted 1:5 or 1:10 correlated with hemagglutination inhibition (HI) and microneutralization

93 al evidence of infection based on results of hemagglutination inhibition (HI) and microneutralization

94 ins collected pre- and postvaccination using hemagglutination inhibition (HI) and microneutralization

95 ationally designed ancestral H5N1 strains by hemagglutination inhibition (HI) and microneutralization

96 When evaluated by hemagglutination inhibition (HI) and microneutralization

97 The H10-directed MAbs displayed functional hemagglutination inhibition (HI) and neutralization acti

98 ne sera and ferret antisera were analyzed by hemagglutination inhibition (HI) and neutralization assa

99 ne sera and ferret antisera were analyzed by hemagglutination inhibition (HI) and neutralization assa

100 lities of H1 HA and H3 HA antigens to elicit hemagglutination inhibition (HI) and neutralizing antibo

101 Viruses were characterized by hemagglutination inhibition (HI) and sequencing of antig

102 correlated with antibody titers measured by hemagglutination inhibition (HI) and virus microneutrali

103 seasonal influenza vaccine (TIV) can affect hemagglutination inhibition (HI) antibody responses to p

104 9 shedding, although the LAIV elicited lower hemagglutination inhibition (HI) antibody titers in seru

105 Hemagglutination inhibition (HI) antibody titers were me

106 Antibody to H3N2v was assessed by hemagglutination inhibition (HI) assay and, for a subset

107 Hemagglutination inhibition (HI) assay data for swine an

108 n of influenza viruses is typically based on hemagglutination inhibition (HI) assay data for viral is

109 in restoring the anti-HA specificity of the hemagglutination inhibition (HI) assay for monitoring an

110 activity between influenza strains using the hemagglutination inhibition (HI) assay.

111 ce of seropositivity (titer >/=40) using the hemagglutination inhibition (HI) assay.

112 Antigenic drift is assessed primarily by the hemagglutination inhibition (HI) assay.

113 m09-specific antibodies were measured by the hemagglutination inhibition (HI) assay.

114 eir antigenic characteristics as measured by hemagglutination inhibition (HI) assay.

115 erum antibody responses were determined by a hemagglutination inhibition (HI) assay.

116 As predicted, hemagglutination inhibition (HI) assays using human sera

117 dividuals using microneutralization (MN) and hemagglutination inhibition (HI) assays.

118 d by microneutralization assays and modified hemagglutination inhibition (HI) assays.

119 t of these introduced substitutions by using hemagglutination inhibition (HI) data with monovalent sw

120 2009 to September 2010) were tested using a hemagglutination inhibition (HI) test.

121 N9 virus led to 23- and 8-fold reductions in hemagglutination inhibition (HI) titer with ferret and c

122 lear differences between individuals with no hemagglutination inhibition (HI) titers (<1:10) and thos

123 ines are able to induce antibodies with high hemagglutination inhibition (HI) titers and completely p

124 In post hoc analyses, hemagglutination inhibition (HI) titers measured at base

125 n this study, the antigenic map derived from hemagglutination inhibition (HI) titers of cell-cultured

126 he impact of repeat influenza vaccination on hemagglutination inhibition (HI) titers, antibody bindin

127 In addition to hemagglutination inhibition (HI) titers, we used H1N1pdm

128 Viruses were characterized by hemagglutination inhibition (HI), and the hemagglutinin

129 accines induce low or undetectable titers of hemagglutination inhibition (HI), cross-HI, and/or virus

130 The humoral response was measured by the hemagglutination inhibition (HI), microneutralization (M

131 r immune responses to the virus, assessed in hemagglutination inhibition (HI), microneutralization, E

132 ative vaccine efficacy (VE), immunogenicity (hemagglutination inhibition [HAI] titers), and safety am

133 between markers of preexisting immunity (ie, hemagglutination inhibition [HAI], microneutralization,

134 ological potency in chickens (geometric mean hemagglutination inhibition [HI] titers, >/= 1:169), but

135 Similar trends are observed with the serum hemagglutination inhibition Ab response after each annua

136 Prevaccination hemagglutination inhibition Ab titer was <1:20 in all ex

137 xplaining its breadth and ability to mediate hemagglutination inhibition across decades of H3N2 strai

138 influenza virus, with significant levels of hemagglutination inhibition activities (>1:40), which we

139 The elicited antisera was assessed for hemagglutination inhibition activity against a panel of

140 a P1 HA-elicited mAb (1F8) exhibiting broad hemagglutination inhibition activity against both season

141 ng MAb previously described, MAb 6F12 has no hemagglutination inhibition activity against influenza A

142 hese five naturally occurring MAbs displayed hemagglutination inhibition activity, suggesting specifi

143 protein and neutralize virus but do not have hemagglutination inhibition activity.

144 ach site in terms of antibody prevalence and hemagglutination inhibition activity.

145 primary outcome was geometric mean titers of hemagglutination inhibition after influenza vaccination.

146 ymptoms, and antiinfluenza antibody titer by hemagglutination inhibition after vaccination.

147 cinated pigs developed significant levels of hemagglutination inhibition and enzyme-linked immunosorb

148 Hemagglutination inhibition and immunoglobulin isotype p

149 e basis of immunologic data sets (i.e., from hemagglutination inhibition and microneutralization assa

150 rologous H2 influenza viruses as measured by hemagglutination inhibition and microneutralization assa

151 odies to H5 and H7 were measured by means of hemagglutination inhibition and microneutralization assa

152 Vietnam/1203/04 vaccine may result in higher hemagglutination inhibition and microneutralization GMTs

153 g seronegative for these viruses in standard hemagglutination inhibition and microneutralization sero

154 e end of the influenza season for testing by hemagglutination inhibition and neuraminidase inhibition

155 ponses and the geometric mean titer of serum hemagglutination inhibition and neutralizing antibodies

156 ch virus induced high titers of NDV-specific hemagglutination inhibition and serum neutralizing antib

157 nt trimeric NCRD, D325A/R343V, showed marked hemagglutination inhibition and viral neutralization, wi

158 With our novel reagents, we found that both hemagglutination inhibition antibodies and total IgGs we

159 Hemagglutination inhibition antibodies were minimal afte

160 We performed hemagglutination inhibition antibody (HI) assays on pres

161 Proportions achieving a hemagglutination inhibition antibody (HIA) titer of 40 o

162 fect of additional vaccinations, the GMTs of hemagglutination inhibition antibody after the first, se

163 ential influenza A(H1N1)pdm09 vaccination on hemagglutination inhibition antibody boosting and waning

164 In both age groups, hemagglutination inhibition antibody geometric mean tite

165 cinations (P< .001) geometric mean titers of hemagglutination inhibition antibody in vaccines with an

166 S03-adjuvanted CC-H5N1 elicited a homologous hemagglutination inhibition antibody response that satis

167 The complete absence of specific hemagglutination inhibition antibody response to A(H3N2)

168 However, in human adults, we observed high hemagglutination inhibition antibody responses toward th

169 Serum hemagglutination inhibition antibody responses were more

170 en at 21-day intervals and serum samples for hemagglutination inhibition antibody responses were obta

171 eactivity of vaccination-induced H3-specific hemagglutination inhibition antibody responses, and cons

172 10 (29%) participants had a >=4-fold rise in hemagglutination inhibition antibody titer after challen

173 Eleven of 15 (73%) employees had baseline hemagglutination inhibition antibody titers >/=40 to swi

174 r) at 1 month postvaccination based on serum hemagglutination inhibition antibody titers against each

175 hat Ban/AF induced higher neutralization and hemagglutination inhibition antibody titers against the

176 Serum hemagglutination inhibition antibody titers against the

177 A single vaccine dose produced higher hemagglutination inhibition antibody titers at day 21 in

178 ers with correspondingly low levels of serum hemagglutination inhibition antibody titers in pheasants

179 ogenicity was assessed by measurement of the hemagglutination inhibition antibody titres in serum for

180 in the geometric mean titers (GMTs) of serum hemagglutination inhibition antibody were observed when

181 The primary immunogenicity outcome was hemagglutination inhibition assay (HAI) titer against ea

182 as antibody titers of 1:40 or greater on the hemagglutination inhibition assay 21 to 28 days after va

183 in-specific antibody responses with standard hemagglutination inhibition assay and by memory B-cell e

184 nd local antibody responses were analysed by hemagglutination inhibition assay and enzyme-linked immu

185 bition assay for influenza A viruses, and by hemagglutination inhibition assay and microneutralisatio

186 anted influenza vaccine underwent testing by hemagglutination inhibition assay for strains not presen

187 city of influenza vaccination exclusively by hemagglutination inhibition assay may be misleading in i

188 Here we use the hemagglutination inhibition assay to analyze the antibod

189 in a subset of subjects were determined by a hemagglutination inhibition assay to determine the subje

190 Horse erythrocyte hemagglutination inhibition assay was performed to detec

191 A hemagglutination inhibition assay was used to assess the

192 on the HA1 domain and antigenic analysis by hemagglutination inhibition assay were carried out.

193 ncy of antibody response (82% vs 50%, by the hemagglutination inhibition assay) and a significantly h

194 he original antigenicity, as determined by a hemagglutination inhibition assay, and effectively prote

195 Humoral responses were evaluated by a hemagglutination inhibition assay, and memory B-cell res

196 evaluated for their antigenic relatedness by hemagglutination inhibition assay, showing that the anti

197 these antibodies do not show activity in the hemagglutination inhibition assay, the hemagglutination

198 Antibody titers were determined by the hemagglutination inhibition assay, using egg- and cell-d

199 timmunization sera underwent strain-specific hemagglutination inhibition assay.

200 posure to influenza was determined using the hemagglutination inhibition assay.

201 old rise in serum antibody titer measured by hemagglutination inhibition assay.

202 ies that are not detected in the traditional hemagglutination inhibition assay.

203 ross-reactive human antibodies detected by a hemagglutination inhibition assay.

204 atedness was assessed by gene sequencing and hemagglutination inhibition assay.

205 tibody responses were determined by means of hemagglutination inhibition assay.

206 mum 4-fold increase to titer >/=40) with the hemagglutination inhibition assay; vaccine-related serio

207 osomes competitively bind influenza virus in hemagglutination inhibition assays and inhibit infection

208 Hemagglutination inhibition assays and sequencing of the

209 antibody concentrations were measured using hemagglutination inhibition assays before immunization,

210 receptor and antibody binding, we conducted hemagglutination inhibition assays using virions and ISV

211 In hemagglutination inhibition assays, 12 antisera cross-re

212 sing flow-through QCM technology, as well as hemagglutination inhibition assays, and compared with do

213 ssays (26.3% and 15.8% by neutralization and hemagglutination inhibition assays, respectively).

214 as assessed by genomic sequence analysis and hemagglutination inhibition assays.

215 s to determine their antigenic properties by hemagglutination inhibition assays.

216 h ferret antisera against MN/10 and BJ/92 in hemagglutination inhibition assays.

217 les were tested with microneutralization and hemagglutination inhibition assays.

218 ax)), relative affinity (K(a)), and level of hemagglutination inhibition in the plasma.

219 thermal titration microcalorimetry (ITC) and hemagglutination inhibition measurements demonstrate tha

220 atistically significant difference in day 42 hemagglutination inhibition seroconversion after mixing

221 coprimary endpoints for noninferiority were hemagglutination inhibition seroconversion rates and pos

222 viruses and vaccines from partially revealed hemagglutination inhibition table.

223 cities by blocking assays; (iv) to develop a hemagglutination inhibition test using buccal cells from

224 0,000-fold less sensitive to the compound in hemagglutination inhibition tests than rSeV(hPIV-1HN).

225 f) to the selective HN inhibitor BCX 2855 in hemagglutination inhibition tests, and slowed its growth

226 It was previously shown by hemagglutination inhibition that measles vaccination in

227 n the hemagglutination inhibition assay, the hemagglutination inhibition titer being the current corr

228 try workers were positive (on the basis of a hemagglutination inhibition titer of >/= 80) for this su

229 immunoglobulin G1 (IgG1) subclass and a high hemagglutination inhibition titer.

230 etermined based on established criterion for hemagglutination inhibition titer; participants with a h

231 ong RT-PCR-confirmed infections in children, hemagglutination inhibition titers >=1:20 were associate

232 Subjects with prevaccination hemagglutination inhibition titers <10 and children 3-<9

233 c) cattle exhibits potent neutralization and hemagglutination inhibition titers against different cla

234 ated antigenic maps based on postvaccination hemagglutination inhibition titers against representativ

235 s vaccination elicited similar serum IgG and hemagglutination inhibition titers and 100% protection a

236 Significantly higher (3-5 fold) hemagglutination inhibition titers and high serum neutra

237 ease in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vacci

238 ited influenza-specific T-cell responses and hemagglutination inhibition titers in response to an MF5

239 The study endpoint was the development of hemagglutination inhibition titers to the strain-specifi

240 Hemagglutination inhibition titers were measured at entr

241 Hemagglutination inhibition titers were sustained for 1

242 nses against CfaE and LTB, as well as strong hemagglutination inhibition titers, a surrogate for neut

243 nfluenza vaccine-specific immunity including hemagglutination inhibition titers, IgA(+) and IgG(+) Ab

244 levels of recall immune responses, including hemagglutination inhibition titers, neutralizing antibod

245 tion rate (anti-influenza antibody titers by hemagglutination inhibition) 21 d after vaccination.

246 assays, receptor-destroying enzyme activity, hemagglutination inhibition, and fluorescence focus neut

247 clude higher neutralization activity, higher hemagglutination inhibition, and more HA stem selectivit

248 ermined 50% protective titers and levels for hemagglutination inhibition, full-length hemagglutinin,

249 1 year post-vaccination) antibody responses (hemagglutination inhibition, influenza-specific IgG) in

250 ere collected to assess immunogenicity using hemagglutination inhibition, microneutralization, and im

251 We evaluated pre- and postchallenge hemagglutination inhibition, neuraminidase inhibition, a

252 za B virus hemagglutinin (HA) head specific, hemagglutination inhibition-inactive monoclonal antibodi

253 stinct, epitope compared with other narrowly hemagglutination inhibition-positive mAbs elicited by th

254 cytometry and vaccine antibody responses by hemagglutination inhibition.

255 d for H5 antibody by microneutralization and hemagglutination inhibition.

256 asma samples were tested for H1/stalkIgG and hemagglutination-inhibition (HAI) antibodies pre-vaccina

257 Serum samples were tested for hemagglutination-inhibition (HAI) antibody increase and

258 We examined hemagglutination-inhibition (HAI) antibody titers in sub

259 Here, we performed hemagglutination-inhibition (HAI) assays, using sera col

260 10), low (GMT = 28.3), or high (GMT > 761.1) hemagglutination-inhibition (HAI) titers to the A/Viet N

261 ficantly enhanced cellular immune responses, hemagglutination-inhibition (HAI) titers, and neutraliza

262 shared strains (A/H3N2 and A/H1N1) based on hemagglutination-inhibition (HI) antibodies 28 days afte

263 n and young adults had the highest levels of hemagglutination-inhibition (HI) antibodies to 2010-2011

264 m samples did not react with Viet/1203/04 in hemagglutination-inhibition (HI) or virus-neutralization

265 Vaccination history, hemagglutination-inhibition (HI) titers, and cell-mediat

266 serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed

267 Safety and immunogenicity (by hemagglutination-inhibition [HI] assay) after each dose

268 Preseason hemagglutination-inhibition and neuraminidase-inhibition

269 Hemagglutination-inhibition and neuraminidase-inhibition

270 letely cleared from nasal samples, and serum hemagglutination-inhibition antibodies were still undete

271 ngle dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects

272 on of participants achieving seroprotection (hemagglutination-inhibition antibody titer >/=1:40 on da

273 rotection and seroconversion rates and lower hemagglutination-inhibition antibody titer geometric mea

274 de 2 HA H5N1 virus-like particles (VLPs) had hemagglutination-inhibition antibody titers that recogni

275 participants had > or = 4-fold increases in hemagglutination-inhibition antibody, and 79% had > or =

276 odies to A(H1N1)pdm09 virus were measured by hemagglutination-inhibition assay in individuals with pa

277 Vaccine immunogenicity was measured by hemagglutination-inhibition assays using reagents expres

278 Hemagglutination-inhibition assays were performed 28 day

279 Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs)

280 ubjects achieved the predetermined endpoint (hemagglutination-inhibition titer > or =40) 28 days afte

281 za vaccine does not result in differences in hemagglutination-inhibition titers in this population, a

282 s reached 1:40 or greater in 54 percent, and hemagglutination-inhibition titers reached 1:40 or great

283 ally increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and ea

284 Hemagglutination mediated by either type 1 or P pili, ad

285 e thiols in F protein when expressed without hemagglutination-neuraminidase (HN) protein but decrease

286 igenic analysis, have been assessed by virus hemagglutination of erythrocytes from different species

287 characteristically mediate mannose-sensitive hemagglutination of guinea pig erythrocytes.

288 diate (i) invasion of epithelial cells, (ii) hemagglutination of rabbit erythrocytes, (iii) interbact

289 Hemagglutination of some F. nucleatum strains is also ga

290 included transient anemia (57% of patients), hemagglutination on peripheral blood smear (36%), fatigu

291 to A/B/O antigens by synthetic HBGA binding, hemagglutination, or saliva binding assays.

292 e fimbriae are associated with adherence and hemagglutination phenotypes in EHEC O157:H7.

293 tem with uniquely integrated surface display hemagglutination (sdHA) antigen and yEGFP reporters.

294 effects on the two red cell species used in hemagglutination, suggesting that these residues play a

295 The indirect hemagglutination test for the detection of antibodies to

296 nation inhibition titer; participants with a hemagglutination titer >/=1:40 plus a >/=4-fold increase

297 etection was significantly improved to 0.032 hemagglutination unit due to the high affinity and high

298 Two definitions of seroprotection (40 hemagglutination units (HAU) and 160 HAU which confers a

299 ic production of hemagglutinin (expressed in hemagglutination units per 10(6) cells) from the siat7e-

300 ithin 1h with a detection limit of 2(-9)HAU (hemagglutination units).